ES3014632T3 - Cannabinoid derivatives - Google Patents

Cannabinoid derivatives Download PDF

Info

Publication number
ES3014632T3
ES3014632T3 ES20841410T ES20841410T ES3014632T3 ES 3014632 T3 ES3014632 T3 ES 3014632T3 ES 20841410 T ES20841410 T ES 20841410T ES 20841410 T ES20841410 T ES 20841410T ES 3014632 T3 ES3014632 T3 ES 3014632T3
Authority
ES
Spain
Prior art keywords
alkyl
pentyl
benzo
dioxino
chromen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20841410T
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey Alan Omeara
Quang Huy To
Patrick Thomas Gunning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canopy Growth Corp
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Application granted granted Critical
Publication of ES3014632T3 publication Critical patent/ES3014632T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES20841410T 2019-07-12 2020-07-10 Cannabinoid derivatives Active ES3014632T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962873686P 2019-07-12 2019-07-12
PCT/CA2020/050966 WO2021007660A1 (en) 2019-07-12 2020-07-10 Cannabinoid derivatives

Publications (1)

Publication Number Publication Date
ES3014632T3 true ES3014632T3 (en) 2025-04-23

Family

ID=74209617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20841410T Active ES3014632T3 (en) 2019-07-12 2020-07-10 Cannabinoid derivatives

Country Status (5)

Country Link
US (1) US20220259221A1 (enExample)
EP (1) EP3997095B1 (enExample)
JP (1) JP2022540432A (enExample)
ES (1) ES3014632T3 (enExample)
WO (1) WO2021007660A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3994114A4 (en) 2019-07-04 2023-08-16 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021007663A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
EP3997098A4 (en) 2019-07-12 2023-10-11 Canopy Growth Corporation Cannabinoid derivatives
WO2021007661A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
JP2022551066A (ja) 2019-10-02 2022-12-07 キャノピー グロウス コーポレイション カンナビノイド誘導体
US12084407B2 (en) 2019-11-26 2024-09-10 Canopy Growth Corporation Cannabigerol derivatives and use thereof as cannabinoid receptor modulators
US12617765B2 (en) 2019-12-09 2026-05-05 Canopy Growth Corporation Cannabinoid derivatives
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
EP4222260A4 (en) * 2020-10-02 2025-01-15 Bessor Pharma, LLC PROCESS FOR THE PRODUCTION OF CANNABINOL, CANNABINOLIC ACID, CANNABIVARIN, CANNABIVARIN ACID AND RELATED CANNABINOIDS
EP4471038A1 (en) 2023-05-30 2024-12-04 Tresco Holding GmbH Process for the synthesis of tetrahydrocannabinolic acid dimethylsiloxane, and tetrahydrocannabinolic acid dimethylsiloxane

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070179135A1 (en) * 2006-01-05 2007-08-02 Travis Craig R Cannabinoid derivatives
CN1377261A (zh) * 1999-03-22 2002-10-30 免疫力药品有限公司 治疗免疫疾病
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
WO2014039042A1 (en) * 2012-09-06 2014-03-13 Northeastern University Novel cannabinergic compounds and uses thereof
US9580400B2 (en) * 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
WO2019234728A1 (en) * 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof
EP3840854A4 (en) * 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives

Also Published As

Publication number Publication date
WO2021007660A1 (en) 2021-01-21
EP3997095C0 (en) 2025-02-12
EP3997095B1 (en) 2025-02-12
EP3997095A4 (en) 2022-12-28
US20220259221A1 (en) 2022-08-18
JP2022540432A (ja) 2022-09-15
EP3997095A1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
EP3997095B1 (en) Cannabinoid derivatives
JP7684945B2 (ja) カンナビノイド誘導体
US12195429B2 (en) Cannabinoid derivatives
EP3997084A1 (en) Cannabinoid derivatives
US12084407B2 (en) Cannabigerol derivatives and use thereof as cannabinoid receptor modulators
US12617765B2 (en) Cannabinoid derivatives
WO2021000053A1 (en) Cannabinoid derivatives
WO2021000054A1 (en) Cannabinoid derivatives
WO2021102569A1 (en) Cannabinoid derivatives
EP4073033A1 (en) Cannabinoid derivatives
EP4065549B1 (en) Cannabinoid derivatives
EP4037676A1 (en) Cannabinoid derivatives
US8546400B2 (en) 1,3-Oxazole-4-carboxamides, 1,3-Thiazole-4-carboxamides, and 1,3-Imidazole-d-carboxamides as Inhibitors of cyclin Dependent kinases